14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PVLA vs ARQT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Arcutis Biotherapeutics, Inc. (ARQT) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas ARQT carries 62.5/100 (BUY) at $27.19 (25.8x Forward P/E, 6.9% operating margin).
Competes within the Biotechnology value chain with $3.5B market capitalization and 6.9% operating margin.
OpEx & R&D Reinvestment84.3% of Rev ($429M)
90D Engineering Disclosures0 Published
Investor FAQ PVLA vs ARQT Key Questions & Quantitative Answers
As of Nov 16, 2026, Arcutis Biotherapeutics, Inc. (ARQT) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas ARQT carries 62.5/100 (BUY) at $27.19 (25.8x Forward P/E, 6.9% operating margin). Technically, PVLA sits in a Neutral phase (RSI 50.9, CONSOLIDATION options structure) and ARQT sits in a Neutral phase (RSI 46.0, CONSOLIDATION options structure).
ARQT leads the Growth & Scale pillar: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ARQT at +45.1% YoY revenue growth and +3.3% YoY earnings growth on $509M TTM revenue (91.2% gross margin, 6.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PVLA cumulative revenue shifted +33.3% while ARQT shifted +533.3%. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus 84.3% of Rev ($429M) (0 disclosures) for ARQT.
ARQT screens cheaper on headline valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ARQT trades at 25.8x Forward P/E, 125.1x Trailing P/E, N/M PEG, and 7.0x EV/Revenue (11.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus ARQT (14.9% ROE) capital efficiency.
In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, ARQT carries 60.7% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.76β · 87% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.